From federal lawmakers to pharmaceutical companies, plans, providers and other health care stakeholders, efforts are coalescing to address social determinants of health (SDOH). Initiatives are ramping up in response to COVID-19’s disparate impact on vulnerable populations and communities across the U.S. and include pharma collaborations with payers and health systems focusing on social determinants relevant to medication adherence and access.
Precision’s Maureen Hennessey weighs in on pharma engagements with payers and health delivery systems, including collaborations to address SDOH, and recommendations for life sciences companies in formulating a corporatewide, sustainable, strategic plan to address SDOH and health disparities.
Read the full article here!
